Drug reference

edaravone

Free-radical scavenger / antioxidant · Anti-ALS

START

60 mg IV over 60 min daily, cycle schedule (or 105 mg oral)

TYPICAL MAX

60 mg IV/day (105 mg oral/day)

STOP IF

Anaphylaxis, significant AKI/hepatotoxicity, or DIC

WATCH

Renal function, LFTs, infusion reactions, sulfite allergy history

CDSCO approvedATC N07XX14

Dose laddermg/d

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 6min · infusion start
PEAK: 1h · end infusion
t½: 7h · t½
DURATION: 1d · daily dose

EXCRETION

Renal — metabolites; some unchanged

route + CYP

INTERACTIONS

—

none in our sources

PREGNANCY

Limited data; use only if clearly needed.

FDA category + note

Mechanism

Pyrazolone free-radical scavenger that quenches hydroxyl radicals and lipid peroxyl radicals, reducing oxidative neuronal injury; mechanism in ALS attributed to slowing motor-neuron oxidative damage.

Indications

Amyotrophic lateral sclerosis (selected patients meeting trial inclusion criteria)Acute ischaemic stroke (selected use in Japan/China — adjunct)

Dosing

Adult: IV: 60 mg IV over 60 min once daily on days 1–14 of an initial 28-day cycle, then 60 mg once daily on 10 of 14 days in subsequent 28-day cycles. Oral suspension 105 mg once daily fasting (approved alternative formulation).
Pediatric: Not established.
Renal adjustment: Caution / not recommended in severe renal impairment.
Hepatic adjustment: Caution in significant hepatic impairment.
Geriatric: No specific adjustment.
Max dose: 60 mg IV/day (or 105 mg oral suspension/day)

Pharmacokinetics

Onset

Neuroprotective effect requires chronic dosing

Peak effect

End of infusion (IV)

Duration

Cycle-based dosing schedule

Half-life

Terminal ~5–9 h

Bioavailability

IV 100%; oral suspension reasonable fasting

Protein binding

~92%

Metabolism

Hepatic conjugation

Excretion

Renal (metabolites; some unchanged)

Contraindications

Severe renal impairment (caution / avoid IV)
Hypersensitivity / sulfite hypersensitivity (asthmatic)
Caution: chronic respiratory failure (oral suspension excipient)

Side effects

Common

Bruising/contusionGait disturbanceHeadacheDermatitisEczema

Serious

Anaphylaxis / serious hypersensitivity
Acute kidney injury (rare)
Hepatotoxicity (rare)
Disseminated intravascular coagulation (reported, stroke use)

Pregnancy & lactation

Pregnancy

Limited data; use only if clearly needed.

Lactation

Limited data; weigh benefit/risk.

Drug interactions

Antiplatelets

Moderate

Database

Bleeding risk in stroke context

Per stroke protocol monitoring